Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

Obeso, J.A., Stamelou, M., Goetz, C.G., Poewe, W., Lang, A.E., Weintraub, D., Burn, D., Halliday, G.M. +30 more·2017·Movement Disorders
DOI 10.1002/mds.27115

Cites (308)

Items 201–281 of 281

  1. Motor subtype in Parkinson's disease: Different disorders or different stages of disease?
    John G. Nutt · 2016 · Movement Disorders
  2. Alpha‐synuclein propagation: New insights from animal models
    Benjamin Dehay, Miquel Vila, Erwan Bézard, Patrik Brundin, Jeffrey H. Kordower · 2015 · Movement Disorders
  3. Parkinson disease and incidental Lewy body disease
    Diego Iacono, Maria Geraci-Erck, Marcie Rabin, Charles H. Adler, Geidy E. Serrano, Thomas G. Beach, Roger Kurlan · 2015 · Neurology
  4. Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates
    Timothy J. Collier, Donald Eugene Redmond, Kathy Steece‐Collier, Jack W. Lipton, Fredric P. Manfredsson · 2016 · Frontiers in Neuroscience
  5. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease
    Flavia Niccolini, Thomas Foltynie, Tiago Reis Marques, Nils Muhlert, Andri C. Tziortzi, Graham E. Searle, Sridhar Natesan, Shitij Kapur, Eugenii A. Rabiner, Roger N. Gunn et al. · 2015 · Brain
  6. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
    Dhanya Vijayakumar, Joseph J. Jankovic · 2016 · Drugs
  7. Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N -Methyl-D-Aspartate Receptor Subunit
    Alessandro Tozzi, Antonio de Iure, Vincenza Bagetta, Michela Tantucci, Valentina Durante, Ana Quiroga‐Varela, Cinzia Costa, Massimiliano Di Filippo, Veronica Ghiglieri, Emanuele Claudio Latagliata et al. · 2015 · Biological Psychiatry
  8. Vascular parkinsonism: Deconstructing a syndrome
    J. A. Vizcarra, A. Lang, K. D. Sethi, A. Espay · 2015 · Movement Disorders
  9. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations.
    Francesco Brigo, R. Erro, A. Marangi, K. Bhatia, M. Tinazzi · 2014 · Parkinsonism & Related Disorders
  10. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease
    Anthony Edward Lang, Jose Angel Obeso · 2004 · Annals of Neurology
  11. The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk
    Caroline M. Tanner, Samuel M. Goldman, G. Webster Ross, Stephen J. Grate · 2014 · Alzheimer s & Dementia
  12. Functional Correlations between Neighboring Neurons in the Primate Globus Pallidus Are Weak or Nonexistent
    Izhar Bar‐Gad, Gali Heimer, Ya’acov Ritov, Hagai Bergman · 2003 · Journal of Neuroscience
  13. Substantia Nigra and Parkinson's Disease: A Brief History of Their Long and Intimate Relationship
    M. Parent, A. Parent · 2010 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  14. Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study
    M. Müller, D. Jennings, R. Albin, N. Bohnen, A. Siderowf, Matthew B. Stern, J. Seibyl, S. Eberly, D. Oakes, Kenneth Marek · 2015 · Neurology
  15. Dopamine, tremor, and Parkinson's disease.
    E. C. Hirsch, A. Mouatt, B. Faucheux, A. Bonnet, A. Graybiel, Y. Agid · 1992 · The Lancet
  16. Levodopa: Effect on cell death and the natural history of Parkinson's disease
    C. Warren Olanow · 2014 · Movement Disorders
  17. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson’s disease
    M. Furlong, Caroline M. Tanner, S. Goldman, Grace S. Bhudhikanok, A. Blair, Anabel R. Chade, K. Comyns, J. Hoppin, M. Kasten, M. Korell et al. · 2014 · Environment International
  18. A practical approach to diagnosing adult onset leukodystrophies
    Rebekah M. Ahmed, Elaine Murphy, Indran Davagnanam, Matthew J. Parton, Jonathan M. Schott, Catherine Jane Mummery, Jonathan Daniel Rohrer, Robin Lachmann, Henry Houlden, Nick C. Fox et al. · 2013 · Journal of Neurology Neurosurgery & Psychiatry
  19. α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
    Ilaria Guella, Daniel M. Evans, Chelsea Szu‐Tu, Ekaterina Nosova, Stephanie Bortnick, SNCA Cognition Study Group, Jennifer G. Goldman, John C. Dalrymple‐Alford, Gert J. Geurtsen, Irene Litvan et al. · 2016 · Annals of Neurology
  20. Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms
    V. Sossi, R. de la Fuente-Fernández, J. Holden, M. Schulzer, T. J. Ruth, J. Stoessl · 2004 · Journal of Cerebral Blood Flow and Metabolism
  21. Genetics of Parkinson's disease: LRRK2 on the rise.
    A. Brice · 2005 · Brain : a journal of neurology
  22. Development of P assive I mmunotherapies for S ynucleinopathies
    Ann‐Louise Bergström, Pekka Kallunki, Karina Fog · 2015 · Movement Disorders
  23. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism
    Sabina Pappatà, Gabriella Santangelo, Dag Aarsland, Caterina Vicidomini, Katia Longo, Kolbjørn Brønnick, Marianna Amboni, Roberto Erro, Carmine Vitale, Maria Grazia Caprio et al. · 2011 · Neurology
  24. The Nonmotor Features of Parkinson's Disease
    Nataliya Titova, Mubasher A. Qamar, К. Ray Chaudhuri · 2017 · International review of neurobiology
  25. Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease
    Kumaran, Ravindran, Cookson, Mark R. · 2015 · Human Molecular Genetics
  26. Somatic mitochondrial DNA mutations in single neurons and glia
    Ippolita Cantuti‐Castelvetri, Michael T. S. Lin, Kangni Zheng, Christine E. Keller-McGandy, Rebecca A. Betensky, Donald R. Johns, M. Flint Beal, David G. Standaert, David K. Simon · 2004 · Neurobiology of Aging
  27. Genetics of Synucleinopathies
    Robert Luke Nussbaum · 2017 · Cold Spring Harbor Perspectives in Medicine
  28. Patients with scans without evidence of dopaminergic deficit: A long‐term follow‐up study
    Amit Batla, Roberto Erro, María Stamelou, Susanne A. Schneider, Petra Schwingenschuh, Christos Ganos, Kailash P. Bhatia · 2014 · Movement Disorders
  29. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
    Glenda Margaret Halliday, Heather McCann, Claire E. Shepherd · 2012 · Expert Review of Neurotherapeutics
  30. The relative phases of basal ganglia activities dynamically shape effective connectivity in Parkinson's disease
    Hayriye Cagnan, Eugene Paul Duff, Peter Brown · 2015 · Brain
  31. Arguing against the proposed definition changes of PD
    Bradley F. Boeve, Dennis W. Dickson, John E. Duda, Tanis J. Ferman, Douglas R Galasko, James E. Galvin, Jennifer G. Goldman, John H. Growdon, Howard I. Hurtig, Daniel Kaufer et al. · 2016 · Movement Disorders
  32. Motor and Nonmotor Features of Carriers of the p.A53T Alpha‐Synuclein Mutation: A Longitudinal Study
    D. Papadimitriou, R. Antonelou, M. Miligkos, M. Maniati, N. Papagiannakis, S. Bostantjopoulou, A. Leonardos, C. Koros, A. Simitsi, S. Papageorgiou et al. · 2016 · Movement Disorders
  33. Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series
    N. Magdalinou, H. Ling, James D. Shand Smith, J. Schott, L. Watkins, A. Lees · 2013 · Journal of Neurology
  34. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease
    Raymond T. Bartus, Tiffany L. Baumann, Lamar Brown, Brian R. Kruegel, Jeffrey M. Ostrove, Christopher D. Herzog · 2012 · Neurobiology of Aging
  35. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease
    A. Schapira, Matthew E. Gegg · 2013 · Proceedings of the National Academy of Sciences of the United States of America
  36. Novel Levodopa Formulations for Parkinson’s Disease
    Maria Eliza Freitas, Marta Ruíz-López, Susan Helen Fox · 2016 · CNS Drugs
  37. The emerging role of transcranial magnetic resonance imaging–guided focused ultrasound in functional neurosurgery
    David Weintraub, W. Jeffrey Elias · 2016 · Movement Disorders
  38. S tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration
    Mónica Sánchez-Contreras, Michael G. Heckman, Pawel M. Tacik, Nancy N. Diehl, Patricia H. Brown, Alexandra I. Soto‐Ortolaza, Elizabeth A. Christopher, Ronald L. Walton, Owen A. Ross, Lawrence I. Golbe et al. · 2016 · Movement Disorders
  39. Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Techniques, Side Effects, and Postoperative Imaging
    C. Hamani, A. Lozano, P. Mazzone, E. Moro, W. Hutchison, P. Silburn, L. Zrinzo, Mesbah Alam, L. Goetz, E. Pereira et al. · 2016 · Stereotactic and Functional Neurosurgery
  40. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?
    Hideaki Matsui, Kazuto Nishinaka, M. Oda, K. Komatsu, T. Kubori, F. Udaka · 2006 · Parkinsonism & Related Disorders
  41. Parkinsonism following neuroleptic exposure: A double‐hit hypothesis?
    Roberto Erro, Kailash P. Bhatia, Michèle Tinazzi · 2015 · Movement Disorders
  42. Abolishing the 1‐year rule: How much evidence will be enough?
    R. Postuma, D. Berg, M. Stern, W. Poewe, C. Olanow, W. Oertel, K. Marek, I. Litvan, Anthony E. Lang, G. Halliday et al. · 2016 · Movement Disorders
  43. “Organic Remains of a Former World”
    H. Tyler, K. Tyler · 1985 · Neurology
  44. An Essay on Wilhelm von Humboldt and the Shaking Palsy
    R. Horowski, L. Horowski, C. Phil, S. Vogel, W. Poewe, F. Kielhorn · 1995 · Neurology
  45. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease
    Haydeh Payami · 2017 · Movement Disorders
  46. A historical analysis of the relationship between encephalitis lethargica and postencephalitic parkinsonism: A complex rather than a direct relationship
    J. Vilensky, S. Gilman, Sherman A. McCall · 2010 · Movement Disorders
  47. Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another?
    Jeffrey H. Kordower, Patrik Brundin · 2008 · Neuropsychopharmacology
  48. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease
    Ruediger Hilker, Noushin Razai, Mehran Ghaemi, S. Weisenbach, Jobst Rudolf, Brigitte Szelies, Wolf‐Dieter Heiss · 2003 · Clinical Neurology and Neurosurgery
  49. New and emerging medical therapies in Parkinson’s disease
    Mitesh Lotia, Joseph J. Jankovic · 2016 · Expert Opinion on Pharmacotherapy
  50. Accuracy of Parkinson disease diagnosis unchanged in 2 decades
    A. H. Rajput, A. Rajput · 2014 · Neurology
  51. Genetics of movement disorders in the next‐generation sequencing era
    Simone Olgiati, Marialuisa Quadri, Vincenzo Bonifati · 2016 · Movement Disorders
  52. Do prions cause Parkinson disease?: The evidence accumulates
    C. Warren Olanow · 2014 · Annals of Neurology
  53. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease
    Dana B. Hancock, E. Martin, K. Fujiwara, Mark A. Stacy, B. Scott, J. Stajich, Rita M. Jewett, Yi-Ju Li, Michael A. Hauser, J. Vance et al. · 2006 · Annals of Neurology
  54. Randomized Controlled Trial of Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Infusion in Parkinson Disease
    A. Verma · 2007
  55. Oscillatory activity in the basal ganglia and deep brain stimulation
    Jorge Guridi, Manuel Alegre · 2016 · Movement Disorders
  56. Did parkinsonism occur before 1817?
    G. Stern · 1989 · Journal of Neurology Neurosurgery & Psychiatry
  57. Flies with Parkinson's disease
    Roeland Vanhauwaert, Patrik Verstreken · 2015 · Experimental Neurology
  58. Advances in surgery for movement disorders
    Nathan Christopher Rowland, Francesco Sammartino, Andrés M. Lozano · 2016 · Movement Disorders
  59. Organic Remains of a Former World: An Examination of the Mineralized Remains of the Vegetables and Animals of the Antediluvian World; Generally Termed Extraneous Fossils
    J. Parkinson · 2013 · Biodiversity Heritage Library (Smithsonian Institution)
  60. Polychlorinated Biphenyls in Prospectively Collected Serum and Parkinson’s Disease Risk
    M. Weisskopf, P. Knekt, É. O'Reilly, J. Lyytinen, A. Reunanen, F. Laden, L. Altshul, A. Ascherio · 2012 · Movement Disorders
  61. Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection
    Paul A. Lapchak, Dalia M. Araujo, Dana C. Hilt, S Jiao, F Collin, Yasuyuki Miyoshi, Yi Ai, Z. Zhang, Don Marshall Gash · 1998 · Brain Research
  62. The shaking palsy, the first forty‐five years: A Journey through the british literature
    E. Louis · 1997 · Movement Disorders
  63. Targeting α‐Synuclein as a therapy for Parkinson's disease: The battle begins
    C. Warren Olanow, Jeffrey H. Kordower · 2017 · Movement Disorders
  64. MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category
    T. Mestre, A. Gupta, A.-E. Lang · 2015 · Journal of Neurology Neurosurgery & Psychiatry
  65. Instrumented Functional Reach Test Differentiates Individuals at High Risk for Parkinson’s Disease from Controls
    S. Hasmann, D. Berg, M. Hobert, D. Weiss, U. Lindemann, J. Streffer, I. Liepelt-Scarfone, W. Maetzler · 2014 · Frontiers in Aging Neuroscience
  66. Cerebrospinal fluid biomarkers and clinical features in leucine‐rich repeat kinase 2 (LRRK2) mutation carriers
    Dolores Vilas, Leslie M. J. Shaw, Peggy Taylor, Daniela Berg, Kathrin Brockmann, Jan Olav Aasly, Connie Marras, Claustre Pont‐Sunyer, José Ríos, KENNETH L. MAREK et al. · 2016 · Movement Disorders
  67. A Scan Without Evidence Is Not Evidence of Absence: Scans Without Evidence of Dopaminergic Deficit in a Symptomatic Leucine-Rich repeat Kinase 2 Mutation Carrier
    Daryl J. Wile, K. Dinelle, N. Vafai, J. McKenzie, Joseph K. C. Tsui, P. Schaffer, Yu-Shin Ding, M. Farrer, V. Sossi, A. Stoessl · 2015 · Movement Disorders
  68. Motor Complications in Parkinson's Disease
    W. Ondo · 2011 · International Journal of Neuroscience
  69. Basic science breaks through: New therapeutic advances in Parkinson's disease
    Patrik Brundin, Graham Atkin, Jennifer T. Lamberts · 2015 · Movement Disorders
  70. Shift to Older Age Distribution in Parkinsonism
    R. Schwab, L. J. Doshay, H. Garland, Peter Bradshaw, E. Garvey, Betty Crawford · 1956 · Neurology
  71. Multitarget disease-modifying therapy in Parkinson's disease?
    Paolo Calabresi, Massimiliano Di Filippo · 2015 · The Lancet Neurology
  72. Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson’s Disease
    James M. Gruschus · 2015 · PLoS ONE
  73. Imaging the Aetiology of Sleep Disorders in Dementia and Parkinson’s Disease
    Nicola Pavese · 2014 · Current Neurology and Neuroscience Reports
  74. Coffee, Genetic Variants, and Parkinson's Disease: Gene–Environment Interactions
    Naomi Yamada-Fowler, Peter Söderkvist · 2015 · Journal of Caffeine Research
  75. An essay on the shaking palsy: Reviews and notes on the journals in which they appeared
    L. Herzberg · 1990 · Movement Disorders
  76. Charcot, the clinician: The Tuesday Lessons: Excerpts from nine case presentations on general neurology delivered at the Salpêtrière hospital in 1887–88 by Jean‐Martin Charcot. Translated with commentary by Christopher G. Goetz. Raven press, New York, 223, illustrated, $56.00, 1987
    S. Fahn · 1989
  77. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions
    Joseph J. Jankovic, Susan Bressman, William T. Dauer, Un Jung Kang · 2015 · Movement Disorders
  78. Genetic risk loci for Parkinson's disease: Moving from state to trait?
    M. Kasten, C. Klein · 2015 · Movement Disorders
  79. Rebuilding the nigrostriatal dopamine pathway: 30 years and counting.
    T. Collier · 2014 · Experimental Neurology
  80. FAMILIAL SPASTIC PARALYSIS
    C. Riggs · 1916
  81. Untitled work
    Kordower · 1999 · 10.1002/1531-8249(199909)46:3